tumour necrosis factor shed form
有货
产品名称 | tumour necrosis factor shed form |
---|
CAS编号和信息 | rp175336 |
---|
UniProtKB | P01375 |
---|---|
Wikipedia | Tumor_necrosis_factor-alpha |
RCSB PDB Structure | 1TNF |
Ensembl Gene | ENSG00000204490 |
DrugBank Target | P01375 |
PEP | tumour necrosis factor alpha |
CATH/Gene3D | 2.60.120.40 |
Immunopaedia Search | tumour necrosis factor shed form |
Target ID | 1870 | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
名称 | tumor necrosis factor receptor 1 | ||||||||||||||||||||||||
缩写名 | TNFR1 | ||||||||||||||||||||||||
家族 | Tumour necrosis factor (TNF) receptor family | ||||||||||||||||||||||||
基因和蛋白信息 |
|
||||||||||||||||||||||||
Ensembl Gene | ENSG00000067182 (Hs) , ENSMUSG00000030341 (Mm) , ENSRNOG00000031312 (Rn) | ||||||||||||||||||||||||
Entrez Gene | 21937 (Mm) , 25625 (Rn) , 7132 (Hs) | ||||||||||||||||||||||||
OMIM | 191190 (Hs) | ||||||||||||||||||||||||
Protein GI | 4507575 (Hs) , 31560799 (Mm) , 6981664 (Rn) | ||||||||||||||||||||||||
UniProtKB | P19438 (Hs) , P25118 (Mm) , P22934 (Rn) | ||||||||||||||||||||||||
ChEMBL Target | CHEMBL3378 (Hs) |
Ligand ID | 5074 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
名称 | tumour necrosis factor shed form | ||||||||||
别名 | cachectin | ||||||||||
类别 | Peptide | ||||||||||
学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide | ||||||||||
生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
||||||||||
评价 |
TNFα is a pro-inflammatory, acute phase cytokine involved in systemic inflammation. The TNF precursor is expressed as a membrane-bound ligand, which is cleaved by TACE/ADAM17 to form this shed (or 'soluble') bioactive cytokine containing just the extracellular domain, and that circulates predominantly as a homotrimer. Recombinant TNF is used as an immunostimulant under the INN tasonermin. Circulating active TNF-α is the principal molecular target of the anti-TNF therapeutics |
||||||||||
配体家族 | Tumor necrosis factor superfamily ligands | ||||||||||
基因/前体 |
|
||||||||||
单字母多肽序列 | VRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL | ||||||||||
三字母多肽序列 | |||||||||||
翻译后修饰 | O-linked glycosylation of serine residue at position 4; disulphide bond formation between cysteine residues at positions 69 and 101 | ||||||||||
化学修饰 |
1. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.. Pharmacol Ther, 117 (2): (244-79). [PMID:18155297] |
2. Crowe JS, Roberts KJ, Carlton TM, Maggiore L, Cubitt MF, Clare S, Harcourt K, Reckless J, MacDonald TT, Ray KP et al.. (2018) Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease.. Sci Rep, 8 (1): (4941). [PMID:29563546] |
3. Gahring LC, Carlson NG, Kulmar RA, Rogers SW. (1996) Neuronal expression of tumor necrosis factor alpha in the murine brain.. Neuroimmunomodulation, 3 (5): (289-303). [PMID:9218250] |